Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jun;57(6):872-876.
doi: 10.1111/jpc.15344. Epub 2021 Jan 19.

Randomised trial of dobutamine versus placebo for low superior vena cava flow in preterm infants: Long-term neurodevelopmental outcome

María Carmen Bravo  1 , Paloma López-Ortego  1 , Laura Sánchez  1 , Jesús Díez  2 , Fernando Cabañas  3 , Adelina Pellicer  1
Affiliations
Randomized Controlled Trial

Randomised trial of dobutamine versus placebo for low superior vena cava flow in preterm infants: Long-term neurodevelopmental outcome

María Carmen Bravo et al. J Paediatr Child Health. 2021 Jun.

Abstract

Aim: Although circulatory impairment during the transitional circulation associates morbidity and mortality, its treatment remains controversial. In a pilot trial on circulatory impairment defined as low superior vena cava (SVC) flow, dobutamine (Db) versus placebo (PL) showed a trend towards improved short-term outcomes. The purpose of this study was to report on the long-term outcome of the infants who were observed for SVC flow patterns.

Methods: Among the 126 infants <31 weeks of gestation prospectively scanned from birth, 28 presented low SVC flow within the first 24 h after birth and received Db (n = 16) or PL (n = 12). Follow-up of survivors included motor assessment and Bayley Scales II or III at 2 years, and the Reynolds Intellectual Assessment Scale at 6 years. Neurodevelopmental impairment (NDI) was defined as: cerebral palsy (Gross Motor Function Classification System ≥ level 2), or a cognitive function score < -2 standard deviations; or moderate or severe hearing or visual impairment. Db group, PL group and normal-flow group were compared.

Results: Eighteen infants died (Db: 5; PL: 2; normal flow group: 11, P = 0.1). Follow-up in survivors was accomplished in 80% and 55% of the cohort at 2 years and 6 years, respectively. No significant difference in the combined outcome (mortality or NDI) was found between the groups (42% Db, 36% PL, 30% normal flow group).

Conclusions: This exploratory analysis did not show any differences in the long-term outcome of infants according to SVC flow patterns or its treatment early after birth.

Keywords: dobutamine; neurodevelopment; preterm; transitional circulation.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Kluckow M, Evans N. Superior vena cava flow in newborn infants: A novel marker of systemic blood flow. Arch. Dis. Child. Fetal Neonatal Ed. 2000; 82: F182-7.
    1. Kluckow M, Evans N. Low superior vena cava flow and intraventricular haemorrhage in preterm infants. Arch. Dis. Child. Fetal Neonatal Ed. 2000; 82: F188-94.
    1. Osborn DA, Evans N, Kluckow M. Hemodynamic and antecedent risk factors of early and late periventricular/intraventricular hemorrhage in premature infants. Pediatrics 2003; 112: 33-9.
    1. Osborn DA, Evans N, Kluckow M, Bowen JR, Rieger I. Low superior vena cava flow and effect of inotropes on neurodevelopment to 3 years in preterm infants. Pediatrics 2007; 120: 372-80.
    1. Bravo MC, López-Ortego P, Sánchez L et al. Randomized, placebo-controlled trial of dobutamine for low superior vena cava flow in infants. J. Pediatr. 2015; 167: 572-8.

Publication types